Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended March 31, 2021 and provided an update on its clinical programs.
Key Operational Highlights
Anticipated Upcoming Milestones
“Our team’s recent efforts have led to the initiation of four clinical trials, key additions to the Board and management team, and the completion of our initial public offering,” said Gregory J. Flesher, President and Chief Executive Officer of Reneo. “With a strengthened capital position, we will continue to advance all of our REN001 clinical programs, as well as explore additional opportunities that will help establish Reneo Pharmaceuticals as a leading developer of drugs for rare diseases.”
Financial Results for the Three Months Ended March 31, 2021
The company reported a net loss of $7.2 million, or $3.48 per share, for the three months ended March 31, 2021, compared to a net loss of $4.4 million, or $2.20 per share, for the same period in 2020. The company had $91.2 million in cash and cash equivalents as of March 31, 2021, exclusive of the net proceeds of approximately $84.8 million from the IPO.
Research and development (R&D) expenses were $5.5 million for the three months ended March 31, 2021, compared to $3.6 million for the same period in 2020. The increase of $1.9 million was primarily due to an increase of $1.5 million related to clinical trial costs associated with the launch of our STRIDE and FORWARD studies and $0.4 million in employee and personnel related costs due to additional headcount required to support our clinical and CMC programs.
General and administrative (G&A) expenses for the three months ended March 31, 2021 were $1.7 million, compared to $0.9 million for the same period in 2020. This increase of $0.8 million was primarily attributable to an increase of $0.8 million in employee and personnel related expenses.
About Reneo Pharmaceuticals
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
About REN001
REN001 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for three rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disorder type V (McArdle disease). For more information on REN001 clinical trials, please see clinicaltrials.gov.
About PMM
PMM are a group of disorders that affect roughly 1 in 5,000 people worldwide. PMM are caused by genetic mutations in the mitochondrial or nuclear DNA that reduce the ability of mitochondria to produce energy from nutrient sources. This energy deficit particularly affects tissues and organs with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness or exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.
About STRIDE
STRIDE is a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to assess the efficacy and safety of 100 mg REN001 administered orally once daily to patients with PMM. Approximately 200 adult PMM patients with alterations in mitochondrial DNA and a history of myopathy are expected to be enrolled into STRIDE. The primary efficacy endpoint of the trial is the change from baseline in the distance walked during a 12-minute walk test after 24 weeks of treatment. Secondary efficacy endpoints include changes from baseline in the Modified Fatigue Impact Scale (MFIS), Patient Global Impression of Change scale (PGIC), and other patient-reported outcomes.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Reneo’s clinical trials, and the regulatory approval path for REN001. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
RENEO PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share and par value data)
| MARCH 31, | DECEMBER 31, | ||||||||
| 2021 | 2020 | ||||||||
| Assets | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 91,221 | $ | 53,613 | |||||
| Prepaid expenses and other current assets | 2,339 | 1,412 | |||||||
| Total current assets | 93,560 | 55,025 | |||||||
| Property and equipment, net | 81 | 69 | |||||||
| Other non-current assets | 1,680 | 127 | |||||||
| Total assets | $ | 95,321 | $ | 55,221 | |||||
| Liabilities, convertible preferred stock and stockholders’ deficit | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 556 | $ | 908 | |||||
| Accrued expenses | 3,374 | 3,672 | |||||||
| Total current liabilities | 3,930 | 4,580 | |||||||
| Deferred rent | 32 | 36 | |||||||
| Total liabilities | 3,962 | 4,616 | |||||||
| Commitments and contingencies (Note 10) | |||||||||
| Series A convertible preferred stock, $0.0001 par value; 24,302,472 shares authorized at March 31, 2021 and December 31, 2020; 24,302,472 shares issued and outstanding at March 31, 2021 and December 31, 2020, liquidation preference of $49,127 at March 31, 2021 and December 31, 2020 | 45,652 | 45,652 | |||||||
| Series B convertible preferred stock, $0.0001 par value; 46,881,028 shares authorized at March 31, 2021 and December 31, 2020; 46,881,028 and 23,440,514 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively; liquidation preference of $94,770 and $47,385 as of March 31, 2021 and December 31, 2020, respectively | 94,424 | 47,068 | |||||||
| Stockholders’ deficit: | |||||||||
| Common stock, $0.0001 par value; 105,000,000 shares authorized at March 31, 2021 and December 31, 2020, 2,148,193 issued and 2,123,733 outstanding at March 31, 2021 and 2,053,070 shares issued and outstanding at December 31, 2020, respectively | — | — | |||||||
| Additional paid-in capital | 3,453 | 2,843 | |||||||
| Accumulated deficit | (52,170 | ) | (44,958 | ) | |||||
| Total stockholders’ deficit | (48,717 | ) | (42,115 | ) | |||||
| Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 95,321 | $ | 55,221 | |||||
RENEO PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(in thousands, except share and per share data)
| THREE MONTHS ENDED MARCH 31, | |||||||||
| 2021 | 2020 | ||||||||
| Operating expenses: | |||||||||
| Research and development | $ | 5,472 | $ | 3,578 | |||||
| General and administrative | 1,742 | 924 | |||||||
| Total operating expenses | 7,214 | 4,502 | |||||||
| Loss from operations | (7,214 | ) | (4,502 | ) | |||||
| Other income | 2 | 71 | |||||||
| Net loss | (7,212 | ) | (4,431 | ) | |||||
| Unrealized gain on short-term investments | — | 6 | |||||||
| Comprehensive loss | $ | (7,212 | ) | $ | (4,425 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (3.48 | ) | $ | (2.20 | ) | |||
| Weighted-average shares used in computing net loss per share, basic and diluted | 2,070,935 | 2,015,029 | |||||||
RENEO PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)
| THREE MONTHS ENDED | |||||||||
| MARCH 31, | |||||||||
| 2021 | 2020 | ||||||||
| Cash flows from operating activities | |||||||||
| Net loss | $ | (7,212 | ) | $ | (4,431 | ) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
| Depreciation and amortization | 10 | 9 | |||||||
| Amortization/accretion on short-term investments | — | (15 | ) | ||||||
| Stock-based compensation | 471 | 92 | |||||||
| Changes in operating assets and liabilities: | |||||||||
| Accounts payable, accrued expenses and other | (927 | ) | 36 | ||||||
| Prepaid expenses and other assets | (929 | ) | (137 | ) | |||||
| Deferred rent | (2 | ) | (1 | ) | |||||
| Net cash used in operating activities | (8,589 | ) | (4,447 | ) | |||||
| Cash flows from investing activities | |||||||||
| Purchase of property and equipment | (25 | ) | (1 | ) | |||||
| Proceeds from maturities of available-for-sale short-term investments | — | 5,200 | |||||||
| Net cash (used in) provided by investing activities | (25 | ) | 5,199 | ||||||
| Cash flows from financing activities | |||||||||
| Proceeds from issuance of Series B convertible preferred stock, net of issuance costs | 47,258 | — | |||||||
| Proceeds from exercise of stock options | 187 | 26 | |||||||
| Costs paid in connection with initial public offering | (1,223 | ) | — | ||||||
| Net cash provided by financing activities | 46,222 | 26 | |||||||
| Net increase in cash and cash equivalents | 37,608 | 778 | |||||||
| Cash and cash equivalents, beginning of period | 53,613 | 17,501 | |||||||
| Cash and cash equivalents, end of year of period | $ | 91,221 | $ | 18,279 | |||||
| Supplemental cash flow information: | |||||||||
| Property and equipment in accounts payable | $ | 2 | $ | — | |||||
| Unpaid Series B convertible preferred stock issuance costs | $ | 19 | $ | — | |||||
| Costs incurred in connection with initial public offering included in accrued expenses | $ | 361 | $ | — | |||||
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.76 |
| Daily Change: | -0.01 -0.56 |
| Daily Volume: | 73,919 |
| Market Cap: | US$58.820M |
March 28, 2024 December 14, 2023 November 13, 2023 October 09, 2023 | |
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORE
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORE